CN119013034A - 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 - Google Patents

用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 Download PDF

Info

Publication number
CN119013034A
CN119013034A CN202380019852.2A CN202380019852A CN119013034A CN 119013034 A CN119013034 A CN 119013034A CN 202380019852 A CN202380019852 A CN 202380019852A CN 119013034 A CN119013034 A CN 119013034A
Authority
CN
China
Prior art keywords
fold
amino acid
seq
agent
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380019852.2A
Other languages
English (en)
Chinese (zh)
Inventor
亚瑟·沙赫特
莫希特·马图尔
大卫·威廉·奥尔达克
苏珊·斯隆
吉尔·亚伯勒
妮可·阿克拉莫夫
黛安娜·马
威廉·C·塔布斯
米凯拉·舒尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Priority to CN202510423645.4A priority Critical patent/CN120346304A/zh
Publication of CN119013034A publication Critical patent/CN119013034A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202380019852.2A 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 Pending CN119013034A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510423645.4A CN120346304A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510423645.4A Division CN120346304A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Publications (1)

Publication Number Publication Date
CN119013034A true CN119013034A (zh) 2024-11-22

Family

ID=85476118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202380019852.2A Pending CN119013034A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白
CN202510423645.4A Pending CN120346304A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510423645.4A Pending CN120346304A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Country Status (10)

Country Link
US (1) US20230390360A1 (https=)
EP (1) EP4475875A1 (https=)
JP (1) JP2025506173A (https=)
KR (1) KR20240148001A (https=)
CN (2) CN119013034A (https=)
AU (1) AU2023219773A1 (https=)
CA (1) CA3243493A1 (https=)
MX (1) MX2024009868A (https=)
TW (1) TW202400218A (https=)
WO (1) WO2023154870A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
CN120346304A (zh) 2025-07-22
KR20240148001A (ko) 2024-10-10
AU2023219773A1 (en) 2024-08-01
US20230390360A1 (en) 2023-12-07
WO2023154870A1 (en) 2023-08-17
MX2024009868A (es) 2024-08-20
CA3243493A1 (en) 2023-08-17
JP2025506173A (ja) 2025-03-07
TW202400218A (zh) 2024-01-01
EP4475875A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
JP7483857B2 (ja) インターロイキン－２作用物質およびその使用
DK1868635T3 (en) METHODS OF TREATING IMMUNE DISEASES IN CONNECTION WITH ORGAN TRANSPLANTATION WITH SOLUBLE, Mutating CTLA4 MOLECULES
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
US20220226442A1 (en) Interleukin-2 agents and uses thereof
CN119013034A (zh) 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
US11603387B2 (en) SOCS mimetics for the treatment of diseases
HK40124714A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
HK40113125A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
HK40098728A (zh) 白介素-2突变体及其用途
CN116997351A (zh) 白介素-2突变体及其用途
HK40110548A (zh) 使用白介素-2制剂的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40113125

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination